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to surgery may have a significant influence 
upon biomarker concentrations measured
Nicolas Kahn1,4, Julia Riedlinger3, Markus Roeßler3, Christina Rabe3, Michael Lindner5,6, Ina Koch5,6, 
Sabine Schott‑Hildebrand5,6, Felix J Herth1,4, Marc A Schneider2,4, Michael Meister2,4 and Thomas R Muley2,4*
Abstract 
Background: Biomarkers can be subtle tools to aid the diagnosis, prognosis and monitoring of therapy and disease 
progression. The validation of biomarkers is a cumbersome process involving many steps. Serum samples from lung 
cancer patients were collected in the framework of a larger study for evaluation of biomarkers for early detection of 
lung cancer. The analysis of biomarker levels measured revealed a noticeable difference in certain biomarker values 
that exhibited a dependence of the time point and setting of the sampling. Biomarker concentrations differed signifi‑
cantly if taken before or after the induction of anesthesia and if sampled via venipuncture or arterial catheter.
Methods: To investigate this observation, blood samples from 13 patients were drawn 1–2 days prior to surgery 
(T1), on the same day by venipuncture (T2) and after induction of anesthesia via arterial catheter (T3). The biomarkers 
Squamous Cell Carcinoma antigen (CanAG SCC EIA, Fujirebio Diagnostics, Malvern, USA), Carcinoembrionic Antigen 
(CEA), and CYFRA 21‑1 (Roche Diagnostics GmbH, Mannheim, Germany) were analyzed.
Results: SCC showed a very strong effect in relation to the sampling time and procedure. While the first two points in 
time (T1; T2) were highly comparable (median fold‑change: 0.84; p = 0.7354; correlation ρ = 0.883), patients showed 
a significant increase (median fold‑change: 4.96; p = 0.0017; correlation ρ = ‑0.036) in concentration when comparing 
T1 with the sample time subsequent to anesthesia induction (T3). A much weaker increase was found for CYFRA 21‑1 
at T3 (median fold‑change: 1.40; p = 0.0479). The concentration of CEA showed a very small, but systematic decrease 
(median fold‑change: 0.72; p = 0.0039).
Conclusions: In this study we show the unexpectedly marked influence of blood withdrawal timing (before vs. 
after anesthesia) and procedure (venous versus arterial vessel puncture) has on the concentration of the protein 
biomarker SCC and to a less extent upon CYFRA21‑1. The potential causes for these effects remain to be elucidated in 
subsequent studies, however these findings highlight the importance of a standardized, controlled blood collection 
protocol for biomarker detection.
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Background
Lung cancer is still the leading cause for cancer related 
death in Europe and North America. Despite advances in 
treatment only 5–15% of patients survive the first 5 years 
after diagnosis, mainly in function of the initial stage of 
the disease [1]. In the era of molecular targeted therapies, 
specific treatments for lung cancer become increasingly 
important and thus makes molecular biomarker discov-
ery more meaningful for lung cancer management [2, 3].
Molecular biomarkers are developed to assist in 
the diagnosis, prognosis and treatment monitoring of 
Open Access
*Correspondence:  thomas.muley@med.uni‑heidelberg.de 
2 Translational Research Unit (STF), Thoraxklinik, University of Heidelberg, 
Amalienstr. 5, 69126 Heidelberg, Germany
Full list of author information is available at the end of the article
Page 2 of 7Kahn et al. Clin Proteom  (2015) 12:19 
diseases. The range of potential marker candidates cov-
ers the wide spectrum of DNA, RNA, proteins, and other 
molecules, which may be derived from all kind of body 
fluids, tissues or even exhaled air (the methylation and 
mutation detection, sequencing, microarrays, and enzy-
matic reactions to name only a few). This in turn has 
driven the development of a number of dedicated diag-
nostic platforms to aid the detection and measurement of 
a new generation of advanced biomarkers.
Major efforts are underway to search and validate 
new biomarkers and extend the range of applications of 
already known biomarkers, as well as fine tune the meth-
ods used to minimize intra- and inter-laboratory vari-
ations. Besides technical aspects, biological variations 
such as diurnal, intra-individual, dietary or long term like 
in potential aging biomarkers, are known and accounted 
for [4].
In this study we focused on variations of well-known 
markers SCC, CYFRA 21-1 and CEA as an effect of 
anesthesia induction, sampling procedure or time of 
sampling. These tumor markers are rarely used for the 
diagnosis of lung cancer due to their lack of sensitiv-
ity and specificity. However, the utility of these markers 
in disease monitoring and prognosis is well established 
[5–15].
The sampling/collection of blood, tissue, or other bio-
specimens required for biomarker determination and 
general diagnostic purposes mostly follows practical clin-
ical workflow considerations. Efforts are generally made 
to standardize blood processing and storage conditions 
[16] but aspects prior to the sample collection procedure 
are very variable and are difficult to control. For exam-
ple the timing of blood collection may significantly differ 
in a hospital versus an outpatient setting. The time point 
for in-patients is often coupled to diagnostic or treatment 
procedures (for example endoscopy, surgery, and anes-
thesia). Apart from these known sources for variation, we 
wish to illustrate certain under-estimated and frequently 
unrecognized sources of variability.
The conditions under which the blood samples from 
study participants are collected are usually inadequately 
annotated in many cases and researchers need to be 
alerted to possible biases caused in assessing new serum/
blood derived biomarkers. In addition, there is a paucity 
of available literature focusing specifically on pre-analyt-
ical research like potential variations in biomarker levels 
before or after specific diagnostic or therapeutic proce-
dures or depending on blood withdrawal procedure.
In order to analyze potential effects of blood sampling 
conditions (i.e. time point: pre-versus post-anesthesia; 
venous versus arterial) on biomarker concentrations we 
selected three well-established markers (i.e. SCC, CEA, 
and CYFRA 21-1) and measured them in a highly anno-
tated fresh cohort of patients.
Results
Serum samples from lung cancer patients of 2 lung can-
cer centers, collected within a framework of a larger Lung 
Cancer Screening project were compared. The biostatis-
tical analysis of several biomarker candidates revealed 
unexpected differences between marker values in lung 
cancer patients depending upon the center where blood 
sampling was performed. The main source of variation in 
marker concentration across both centers could be attrib-
uted to the fact whether a patient underwent surgery 
or not. This effect was also visible in surgical patients 
with COPD. In Fig. 1 an example is given for SCC. The 
effect was evident especially for samples withdrawn 
from patients in center 2. After reviewing the process of 
blood sampling in more detail we established that blood 
samples of patients undergoing surgery in center 2 were 
taken shortly after the induction of anesthesia via arterial 
catheter. In contrast, the blood specimens from cancer 
patients in center 1, as well as control cases from addi-
tional sites were exclusively collected prior to anesthesia 
by venipuncture (time: T1). This prompted us to analyze 
the common effect of anesthesia and procedure of blood 
withdrawal (venous versus arterial).
In Fig.  2 the individual time courses in patients for 
all three markers are shown. There is a strong increase 
of the average SCC concentration at time 3 (T3). For 
CYFRA21-1 a moderate increase of average concentra-
tions at T3 is seen and CEA shows a weak but system-
atic decrease. Although there might be the impression 
that the differences in CEA are due to 2 patients with 
higher CEA values, it is shown in figure that all patients 
but one had systematically decreased values (Fig.  3). 
Fold changes (ratios) between individual points in time 
are summarized in Table 1 and shown in Fig. 3. The fold 
change for SCC is significantly increased at T3 compared 
to T1 (p = 0.0017) and T2 (p = 0.0002). The median fold 
change between time T1 and T3 is most pronounced in 
SCC (~5 fold) compared to CEA (0.72 fold) and CYFRA 
21-1 (1.4 fold). In Fig. 4 the correlation between marker 
concentrations at T1 and T2, T1 and T3 and T2 and T3 is 
shown. The correlation between T1 and T2 is fairly good 
for all markers. On the other hand, there is no correlation 
between T1 and T3 and T2 and T3 for SCC (ρ = −0.036 
and ρ = −0.126, respectively).
A similar but much weaker effect upon the correlation 
of marker concentrations between points in time can be 
seen for CYFRA 21-1. There is a decrease in the corre-
lation coefficient from greater 0.8 to less than 0.7. Most 
data points show an increase in concentration at T3 
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compared to T1 and T2. However, CEA shows a good 
correlation (ρ > 0.9) for all time points.
Discussion
Using standardized and commercially available assays 
to validate candidate biomarkers has been proven to 
be feasible and reliable. Biobanks are considered as an 
important source for rapidly available samples with good 
clinical characterization. However, many biobanks sup-
plied by multicenter studies suffer from inadequately 
characterized pre-analytical variables that may have a 
major impact on marker concentrations detected.
In this regard, there are international efforts to better 
characterize biospecimens by annotating pre-analytical 
variables that may have an influence on biomarker lev-
els. Betsou et al. [16] suggested the use of SPREC coding 
(sample PREanalytical code). However, in the proposal, 
specific codes for the time point of sampling and for 
procedures (venipuncture versus arterial sampling vs. 
capillary sampling) have not been considered so far. The 
Fig. 1 Results of SCC measurement in two centers in respect to whether the patient underwent surgery (OP) or not (no OP). There is an increase 
in SCC concentrations in center 2 that can be attributed to the presences or absence of surgery independent from common clinical variables like 
gender, stage, age and histology.
Fig. 2 Individual time courses for each marker.
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main focus of SPREC was on sample processing and 
storage conditions. However, our results clearly suggest, 
that variables prior to sample acquisition should be also 
annotated.
Patient derived factors of variance such as fasting, exer-
cise and particularly medication, may be expected to 
show a considerable influence on biomarker levels seen. 
Tranquillizers taken prior to surgery or endoscopy or 
drugs used prior to the induction of anesthesia may also 
affect marker levels seen. Furthermore, it is known that 
the method of sample collection i.e. venipuncture ver-
sus arterial catheter versus capillary puncture may have 
an influence on the measurement of small molecules (for 
example platelet–monocyte aggregates) [17]. However, it 
is difficult to separate the effect of arterial versus venous 
blood sampling on tumor marker levels without the 
additional effect of anesthesia. Arterial blood sampling 
performed in the manner used in our study certainly 
requires anesthesia. The latter we think is the more 
important confounder in our setup.
Apart from variability induced by the blood sampling 
technique used; inter- and intraassay variation and bio-
logical variation could contribute to differences in meas-
ured values in our study. As all samples were measured 
within one assay run, interassay variation did not play 
a role in our study. For CEA, repeatability has been 
reported by the manufacturer (Roche, Elecsys) as being 
between 1.3 and 5.0% depending on the amount of ana-
lyte in the sample (technical bulletin CEA, Roche). For 
CYFRA 21-1 the corresponding values were reported as 
between 1.6 and 2.1% (technical bulletin CYFRA 21-1 
Roche). Respective data for SCC were between 1.9 and 
2.4% (technical bulletin SCC CanAG Fujirebio). The bio-
logical variation of CEA, CYFRA 21-1 and further mark-
ers were analysed by Trapé et al. [18]. They did not find 
significant differences in biological variation for CEA and 
CYFRA 21-1 between the control group and lung cancer 
patients.
At least for the tumor markers that we analysed, there 
are no reports available on circadian differences as a 
potential source of within-patient variation, for example 
when a blood sample is withdrawn in the morning, in 
the afternoon or evening from the same patient To date 
we do not fully understand the mechanisms by which 
the concentration alterations were induced. However, it 
seems to be very unlikely that the changes that we have 
seen in protein tumor marker levels might be caused by 
de novo synthesis or degradation of protein within the 
relatively short time period between induction of anes-
thesia and blood collection. It is more likely that the 
changes have been induced by biomarker release from 
Fig. 3 Boxplot of ratios of tumor marker levels at points in time T1–T3.
Table 1 Distribution of marker value ratios
* p value corresponds to the Wilcoxon signed rank sum test for paired data.
Biomarker Time ratio Mean Median Min–max p value*
SCC T2/T1 1.06 0.84 0.11–2.44 0.7354
T3/T1 7.42 4.96 0.74–22.79 0.0017
T3/T2 18.84 3.99 1.06–175.67 0.0002
CEA T2/T1 0.87 0.88 0.72–1.00 0.0059
T3/T1 0.70 0.72 0.48–1.00 0.0039
T3/T2 0.82 0.83 0.55–1.14 0.0665
CYFRA 21‑1 T2/T1 1.12 1.11 0.61–1.57 0.2661
T3/T1 1.51 1.40 0.70–3.36 0.0479
T3/T2 1.34 1.18 0.85–2.43 0.0269
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reservoirs in response to the medication, for example 
from interstitial space, or cell cytoplasm. Small variations 
or decreasing marker levels, as we described in case of 
CEA may be attributable to differences in venous versus 
arterial blood levels. Another possible explanation would 
be a direct interference of the drug (anesthetics) with the 
immunoassay. However, the underlying mechanism for 
this alteration and differences in respect to specific sub 
cohorts for example gender, age and race remains to be 
elucidated in further studies. This requires obviously 
larger patient cohorts and in vitro experiments. However, 
this was clearly not the scope of the present study.
We acknowledge that our study population is a rather 
small with some heterogeneity in respect to underlying 
lung disease. However, the number of patients was ade-
quate to provide significant results in robust Wilcoxon 
test, and which is known not to be influenced by extreme 
values.
Furthermore, there is a lack of available literature focus-
ing specifically on systematic pre-analytical research, 
particularly upon potential variability seen in biomarker 
levels at different sampling times or before and after spe-
cific diagnostic or therapeutic procedures. To date we 
are aware of only one study that evaluated similar blood 
Fig. 4 Scatterplots of marker concentrations at various points in time. The plots show marker concentrations at T1 versus T2, T1 versus T3 and T2 
versus T3 for each marker together with fitted regression lines according to Passing Bablok [17].
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sampling conditions in relation to the concentration of 
established tumor markers (CA 125, prolactin) in ovar-
ian cancer. Thorpe et  al. [19] established that the time 
point of blood sampling (before surgery and after induc-
tion of anesthesia) had a direct effect on prolactin levels. 
Our study shows, that if conditions of the blood sampling 
are not highly annotated the results seen might eventu-
ally lead to misinterpretation of results (for comparison 
see Fig. 1). However, the biological as well as the clinical 
relevance of our findings remains to be defined.
In summary, there are two important results from this 
study—first, biomarker values may be systematically 
biased if the sample is taken prior to surgery or subse-
quent to anesthesia in the operation theatre, and sec-
ondly, the influence, such as increase, decrease or stable 
concentration of individual markers may be different for 
each marker and cannot be predicted.
There are two ways out from this dilemma, first, to 
check the influence of every potential variable on marker 
concentration and second to minimize variation between 
centers by controlling for all currently known preanalyti-
cal parameters which might influence the measurement 
results.
The latter might be accomplished by better annotating 
pre-analytical variables which might facilitate the selec-
tion of samples with common pre-analytical history. One 
initial step in this direction might be the introduction 
of SPREC coding. However, SPREC should be supple-
mented with preprocessing patient derived variables as 
proposed by this study.
Conclusions
We conclude that the non-adherence to sampling proto-
cols for biomarker validation studies imposes a significant 
risk for bias. These results are a caveat for researchers to 
ensure that all biomarker sampling protocols are con-
trolled for these type of influences.
Methods
Blood specimens were taken from 13 consecutively 
recruited patients at different time points prior to sur-
gery. Blood samples were withdrawn 1–2  days prior to 
surgery by venipuncture (T1) between 8 and 12 a.m., on 
the day of surgery before anesthesia by venipuncture (T2) 
and after induction of anesthesia via an arterial catheter 
(T3). There were 10 male and 3 female patients. The mean 
age was 59  years. One patient had a hamartoma of the 
lung, 3 patients underwent resection for lung-metastasis 
from non-pulmonary primary cancers and 9 patients suf-
fered from non-small cell lung cancer (NSCLC) (Table 2). 
All samples were taken prior to any surgery. The patients 
underwent no specific cancer treatment in between the 
sampling intervals.
Sample collection, processing and storage were per-
formed in standardized manner. Briefly, samples were 
allowed to clot for 60  min and centrifuged for 10  min 
at 2,000×g at 10°C. Supernatants were stored in 1  ml 
aliquots at −80°C before use. All samples had the 
same SPREC code (SER-ZZZ-A-D-N-B-D; according 
SPRECbase v1.0) [16]. All samples were measured as uni-
cates for automated ELECSYS assays and as duplicates in 
case of SCC in a single run. The following markers were 
analyzed according to manufacturer’s instructions: Squa-
mous Cell Carcinoma antigen (SCC) (CanAG SCC EIA, 
Fujirebio Diagnostics, Malvern, USA), CYFRA 21-1 and 
Carcinoembrionic Antigen (CEA) Roche Diagnostics 
GmbH, Mannheim, Germany).
Statistical methods
Statistical analysis was performed using R version 2.13.2 
(http://www.R-project.org/.). For each marker candidate 
the correlation between different blood samplings was 
assessed by scatterplots together with Spearman’s corre-
lation coefficient ρ and a Passing Bablok linear regression 
fit [20]. The regression line is only fitted in case there is 
a correlation between measurement values. Differences 
between sampling times are expressed in terms of ratios. 
Ratios correspond to the observed fold changes and allow 
for a comparison of effect size between marker candi-
dates. Statistical differences between the various sam-
pling time points were assessed using Wilcoxon signed 
rank test. A p value <0.05 was considered significant.
Abbreviations
CEA: carcinoembrionic antigen; CYFRA 21‑1: cytokeratin fragment 21‑1; SCC: 
squamous cell carcinoma; NSCLC: non‑small cell lung cancer; SCLC: small cell 
lung cancer; COPD: chronic obstructive pulmonary disease; SPREC: sample 
PREanalytical code.
Table 2 Patient characteristics
Pat. nr. Age Gender Diagnosis
1 83 M NSCLC
2 55 M NSCLC
3 22 M Lung metastasis
4 55 F NSCLC
5 65 F NSCLC
6 61 M NSCLC
7 70 M NSCLC
8 68 M NSCLC
9 62 F NSCLC
10 57 M NSCLC
11 50 M Hamartoma
12 59 M Lung metastasis
13 64 M Lung metastasis
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